Genentech wins FDA approval for first adjuvant therapy for ALK-positive, early NSCLC
Roche’s subsidiary Genentech has successfully expanded the label of Alecensa to include the adjuvant treatment of anaplastic lymphoma kinase-positive, early-stage non-small cell lung cancer following resection.